News Transcontinental strategic alliance for cutting-edge orthopaedic medicine
HSS and Schulthess Klinik strengthen collaboration in therapy and research.
Yesterday, Zurich became the international capital of medical excellence in orthopaedics: Schulthess Klinik, ranked by Newsweek and Statista as the best orthopaedic clinic in Switzerland, number 2 in Europe and number 6 worldwide, welcomed a delegation from the Hospital for Special Surgery (HSS) in New York – ranked #1 in orthopaedics in the US for the past 16 years. The two institutions are intensifying their collaboration to advance orthopaedic medicine through shared expertise, collaborative research and innovative treatment approaches.
A wide-ranging alliance spanning clinical care and training as well as research
The collaboration is founded on four main objectives: promote the continuous exchange of knowledge and expertise, expand scientific collaboration through joint research initiatives, focus on the shared development of education and training programmes to support professional growth, and collaborate on administrative and technological matters. This will ensure a holistic and forward-looking approach to advancing orthopaedic medicine.
Joint research initiatives are a central focus of the collaboration. At the heart of these efforts is the integration of emerging technologies such as apps, wearables, motion analysis and artificial intelligence. These tools support the development of personalised treatment approaches by enabling more precise functional assessments and patient-specific insights. The findings are expected to contribute to further improved long-term treatment outcomes and quality of life for patients.
Specialists from both institutions will have the opportunity to participate in reciprocal observerships. The long-standing exchange programme, which has been in place for over 15 years, will be expanded to include a structured fellowship programme with clearly defined training objectives. In addition, regular continuing education activities will be established to further strengthen professional development.
Working together for patient well-being
Rodolphe Eurin, CEO of Schulthess Klinik, said: “We are delighted about the alliance with HSS. It will enable us to strengthen international knowledge transfer and sends a clear signal for the continued advancement of cutting-edge orthopaedic medicine and its outcomes. Together, we are improving the quality of life for orthopaedic patients around the world."
Prof. Dr. med. Michael Leunig, Chief Medical Officer and Head of Hip Surgery at Schulthess Klinik, said: "Through targeted exchange of experiences and best practices with HSS and other leading clinics and research institutions, we can not only further advance our medical excellence, but also jointly advance innovative research projects and ensure the highest standard of patient care in the long term."
Bryan T. Kelly, MD, MBA, President & CEO and Surgeon-in-Chief Emeritus of the HSS, also emphasised the importance of this collaboration: “The further strengthening of our relationship with Schulthess Klinik, one of Europe’s leading orthopaedic clinics, marks an important milestone in the expansion of our international network. Together, we can share and deepen our expertise, further advance therapies, and improve medical training for the benefit of patients. Our goal is to raise the global standards of orthopaedic care and make world-class care even more widely accessible.”
On the photo:
Ernest L. Sink, MD, Pediatric Orthopedic and Hip Preservation Surgeon, HSS
Prof. Dr. med. Michael Leunig, CMO, Head of Hip Surgery, Schulthess Klinik
Prof. Dr. habil. Annegret Mündermann, PhD, Chair of Research, Schulthess Klinik
Daniel W. Green, MD, MS, FAAP, FACS, Pediatric Orthopedic and Sports Medicine Surgeon, HSS
Rodolphe Eurin, Director and CEO, Schulthess Klinik
About HSS
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is New York City-based Hospital for Special Surgery, ranked in the United States No. 1 in orthopedics (for the 16th consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2025-2026). Founded in 1863, the Hospital has the lowest readmission rates in the U.S. for orthopedics, and among the lowest infection and complication rates. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.
